Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer (including adenocarcinoma or squamous cell), and it can be measured on scans
- You have not had chemotherapy or immunotherapy for advanced lung cancer before starting this study
- You must be 18 or older, and be well enough to do daily activities (ECOG 0 to 2)
- If you have cancer in the brain, it must be no symptoms or treated and stable
- Your blood tests and organ health must be strong enough (specific counts for white blood cells, platelets, hemoglobin, and liver/kidney function)
- Your tumor PD-L1 must be at least 1% (and if PD-L1 can’t be measured, you may still qualify)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Hear when a new Stage IV Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.